lung cancer Archives

Oncotarget News

Figure 1: Response to docetaxel in second or third line treatment for non-small cell lung cancer after a treatment with chemo-immunotherapy.

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

June 7, 2023

large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.”BUFFALO, NY- June 7, 2023 –... read more

Figure 7: Effects of TGF-β receptor inhibitor EW7197 with and without TGF-β1 for LSR, TRIC, OCLN, and CLDN-2 in human lung epithelial cells (HLE) cells with and without 10% FBS.

Oncotarget

Downregulation of Angulin-1/LSR Induces Malignancy in Lung Adenocarcinoma

March 29, 2023

In the present study, we found that downregulation of angulin-1/LSR induced malignancy via upregulation of EGF-dependent CLDN-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma.” BUFFALO, NY-... read more

Figure 5: NSL-YHJ-2-27 suppresses cancer cell migration and invasion.

Oncotarget

Oncotarget | Polyisoprenylated Cysteinyl Amide Inhibitors Deplete G-Proteins in Cancer Cells

March 28, 2023

mutations in G-proteins have been associated in the progress of several cancers [...]” BUFFALO, NY- March 28, 2023 – A new research paper was published in Oncotarget's Volume 14 on March... read more

Oncotarget

Oncotarget | Tumor Hyaluronan as Novel Biomarker in Non-Small Cell Lung Cancer: A Retrospective Study

November 9, 2022

To the best of our knowledge, there have only been 2 other studies (both retrospective) investigating the prognostic potential of HA in NSCLC patients [5, 6].”BUFFALO, NY- November 9,... read more

Oncotarget

Oncotarget | Therapeutic Efficacy of Humanized JAA-F11 Anti-Thomsen-Friedenreich Antibody Constructs H2aL2a and H3L3 in Human Breast and Lung Cancer Xenograft Models

October 25, 2022

The potential therapeutic efficacy of the humanized antibodies to TF-Ag-α, hJAA-F11-H2aL2a and hJAA-F11-H3L3, was assessed in human breast and lung cancer xenograft models.”BUFFALO, NY- October 25, 2022 – A new... read more

Oncotarget

Behind the Study: Molecular Characterization of Lung Carcinomas Expressing KK-LC-1

July 11, 2022

Dr. Robert Hsu from the University of Southern California, Norris Comprehensive Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of... read more

Oncotarget

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

June 14, 2022

Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in... read more

Figure 2: TMB distribution in non-small cell lung cancer

Oncotarget

Mutational Burden in Lung Cancer Studied in Multisite Cohort

April 25, 2022

BUFFALO, NY-April 25, 2022 – A new research paper, entitled, “Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study,” was published in Oncotarget... read more

Oncotarget

Behind the Study: Targeting Stem Cells in Non-Small Cell Lung Cancer

March 25, 2022

Dr. Beatrice Aramini and Dr. Valentina Masciale from the University of Modena and Reggio Emilia details a 2020 research paper she co-authored and published by Oncotarget, entitled, “CD44+/EPCAM+... read more

Dr. Aditya Kulkarni from The Lantern Pharma, Inc.

Oncotarget

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

August 16, 2021

Behind the Study is a series of transcribed videos from researchers elaborating on their recent oncology-focused studies published by Oncotarget. A new Behind the Study is released each... read more